- Home
- PSBD vs TRML Comparison
PSBD vs TRML Comparison
Compare PSBD & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- TRML
- Stock Information
- Founded
- PSBD 2009
- TRML 2021
- Country
- PSBD United States
- TRML United States
- Employees
- PSBD N/A
- TRML N/A
- Industry
- PSBD
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- TRML Health Care
- Exchange
- PSBD Nasdaq
- TRML Nasdaq
- Market Cap
- PSBD 519.7M
- TRML 419.1M
- IPO Year
- PSBD 2024
- TRML N/A
- Fundamental
- Price
- PSBD $15.67
- TRML $21.86
- Analyst Decision
- PSBD Buy
- TRML Strong Buy
- Analyst Count
- PSBD 7
- TRML 6
- Target Price
- PSBD $16.93
- TRML $54.00
- AVG Volume (30 Days)
- PSBD 22.1K
- TRML 179.5K
- Earning Date
- PSBD 02-08-2025
- TRML 11-07-2024
- Dividend Yield
- PSBD 11.96%
- TRML N/A
- EPS Growth
- PSBD N/A
- TRML N/A
- EPS
- PSBD N/A
- TRML N/A
- Revenue
- PSBD N/A
- TRML N/A
- Revenue This Year
- PSBD N/A
- TRML N/A
- Revenue Next Year
- PSBD N/A
- TRML N/A
- P/E Ratio
- PSBD N/A
- TRML N/A
- Revenue Growth
- PSBD N/A
- TRML N/A
- 52 Week Low
- PSBD $15.27
- TRML $12.12
- 52 Week High
- PSBD $17.12
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- PSBD 42.19
- TRML 37.97
- Support Level
- PSBD $15.59
- TRML $21.23
- Resistance Level
- PSBD $16.10
- TRML $22.80
- Average True Range (ATR)
- PSBD 0.33
- TRML 1.75
- MACD
- PSBD 0.00
- TRML -0.32
- Stochastic Oscillator
- PSBD 12.25
- TRML 11.83
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.